IP Library › Granted Patent US 12,565,492
Granted Patent B2
US 12,565,492 · App. 19/357,447 · Granted Mar 3, 2026

Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof

Inventor: Daniel La (Lexington, MA)
Assignee: Triana Biomedicines, Inc.
C07D413/14A61K31/454
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,565,492
App. No.
19/357,447
Granted
Mar 3, 2026
Kind
B2
Abstract

Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.

Claims (7)

1 . A compound having the structural formula:

2 . A compound having the structural formula:

or a pharmaceutically acceptable salt thereof.

3 . A pharmaceutical composition comprising a compound having the structural formula:

and a pharmaceutically acceptable carrier.

4 . A pharmaceutical composition comprising a compound having the structural formula:

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2025
From: LA, DANIEL
To: TRIANA BIOMEDICINES, INC.
Reel/Frame 073202/0479 →
Continuity (5)
Continuation PCTUS2025041205 · Aug 8, 2025
Provisional Application 63757500 · Feb 12, 2025
Provisional Application 63723238 · Nov 21, 2024
Provisional Application 63681229 · Aug 9, 2024
Related Publication 20260042752A1 · Feb 12, 2026
References Cited (121)
US 9108978B2 · Abell et al. · 2015 [cited by applicant]
US 11485726B2 · Shu · 2022 [cited by applicant]
US 11970486B2 · Le Bourdonnec et al. · 2024 [cited by applicant]
US 20110196150A1 · Man et al. · 2011 [cited by applicant]
US 20190192668A1 · Mainolfi et al. · 2019 [cited by applicant]
US 20240300938A1 · Le Bourdonnec et al. · 2024 [cited by applicant]
US 20240400546A1 · Le Bourdonnec et al. · 2024 [cited by applicant]
CN 111848599A · 2020 [cited by applicant]
CN 114507235A · 2022 [cited by applicant]
CN 117720517A · 2024 [cited by applicant]
CN 117924264A · 2024 [cited by applicant]
CN 118184639A · 2024 [cited by applicant]
CN 118206558A · 2024 [cited by applicant]
CN 118217287A · 2024 [cited by applicant]
CN 118255780A · 2024 [cited by applicant]
CN 118271316A · 2024 [cited by applicant]
CN 118290446A · 2024 [cited by applicant]
CN 118359589A · 2024 [cited by applicant]
CN 118834218A · 2024 [cited by applicant]
CN 118852145A · 2024 [cited by applicant]
CN 118852213A · 2024 [cited by applicant]
CN 119306706A · 2025 [cited by applicant]
WO 2004014370A2 · 2004 [cited by applicant]
WO 2008039489A2 · 2008 [cited by applicant]
WO 2010053732A1 · 2010 [cited by applicant]
WO 2011060392A1 · 2011 [cited by applicant]
WO 2012018668A1 · 2012 [cited by applicant]
WO 2013040647A1 · 2013 [cited by applicant]
WO 2014110558A1 · 2014 [cited by applicant]
WO 2014179661A1 · 2014 [cited by applicant]
WO 2015066515A1 · 2015 [cited by applicant]
WO 2015177110A1 · 2015 [cited by applicant]
WO 2017197051A1 · 2017 [cited by applicant]
WO 2018064356A1 · 2018 [cited by applicant]
WO 2018081167A1 · 2018 [cited by applicant]
WO 2018160356A1 · 2018 [cited by applicant]
WO 2019018795A1 · 2019 [cited by applicant]
WO 2019038717A1 · 2019 [cited by applicant]
WO 2019060693A1 · 2019 [cited by applicant]
WO 2019060742A1 · 2019 [cited by applicant]
WO 2019079569A1 · 2019 [cited by applicant]
WO 2019084157A1 · 2019 [cited by applicant]
WO 2019099868A2 · 2019 [cited by applicant]
WO 2019209948A1 · 2019 [cited by applicant]
WO 2020113233A1 · 2020 [cited by applicant]
WO 2020115200A1 · 2020 [cited by applicant]
WO 2020173440A1 · 2020 [cited by applicant]
WO 2020200291A1 · 2020 [cited by applicant]
WO 2020251971A1 · 2020 [cited by applicant]
WO 2021009306A1 · 2021 [cited by applicant]
WO 2021124172A1 · 2021 [cited by applicant]
WO 2021127586A1 · 2021 [cited by applicant]
WO 2021170109A1 · 2021 [cited by applicant]
WO 2021173995A2 · 2021 [cited by applicant]
WO 2021188948A1 · 2021 [cited by applicant]
WO 2022012622A1 · 2022 [cited by applicant]
WO 2022012623A1 · 2022 [cited by applicant]
WO 2022029573A1 · 2022 [cited by applicant]
WO 2022033548A1 · 2022 [cited by applicant]
WO 2022058878A1 · 2022 [cited by applicant]
WO 2022143856A1 · 2022 [cited by applicant]
WO 2022171123A1 · 2022 [cited by applicant]
WO 2022216573A1 · 2022 [cited by applicant]
WO 2022228556A1 · 2022 [cited by applicant]
WO 2023274347A1 · 2023 [cited by applicant]
WO 2023283610A1 · 2023 [cited by applicant]
WO 2023019166A1 · 2023 [cited by applicant]
WO 2023023537A1 · 2023 [cited by applicant]
WO 2023049790A2 · 2023 [cited by applicant]
WO 2023059792A1 · 2023 [cited by applicant]
WO 2023072270A1 · 2023 [cited by applicant]
WO 2023098656A1 · 2023 [cited by applicant]
WO 2023125907A1 · 2023 [cited by applicant]
WO 2023125908A1 · 2023 [cited by applicant]
WO 2023138607A1 · 2023 [cited by applicant]
WO 2023139199A1 · 2023 [cited by applicant]
WO 2023183540A1 · 2023 [cited by applicant]
WO 2023208165A1 · 2023 [cited by applicant]
WO 2023232133A1 · 2023 [cited by applicant]
WO 2023237049A1 · 2023 [cited by applicant]
WO 2023244817A1 · 2023 [cited by applicant]
WO 2023249970A1 · 2023 [cited by applicant]
WO 2023250029A1 · 2023 [cited by applicant]
WO 2024012570A1 · 2024 [cited by applicant]
WO 2024019103A1 · 2024 [cited by applicant]
WO 2024039901A2 · 2024 [cited by applicant]
WO 2024050078A1 · 2024 [cited by applicant]
WO 2024054832A1 · 2024 [cited by applicant]
WO 2024056005A1 · 2024 [cited by applicant]
WO 2024059525A2 · 2024 [cited by applicant]
WO 2024102849A1 · 2024 [cited by applicant]
WO 2024118960A1 · 2024 [cited by applicant]
WO 2024118966A1 · 2024 [cited by applicant]
WO 2024149349A1 · 2024 [cited by applicant]
WO 2024151547A1 · 2024 [cited by applicant]
WO 2024167999A1 · 2024 [cited by applicant]
WO 2024192146A2 · 2024 [cited by applicant]
WO 2024193464A1 · 2024 [cited by applicant]
WO 2024209044A1 · 2024 [cited by applicant]
WO 2024217481A1 · 2024 [cited by applicant]
WO 2024220843A1 · 2024 [cited by applicant]
WO 2024222614A1 · 2024 [cited by applicant]
WO 2024233846A1 · 2024 [cited by applicant]
WO 2024259216A1 · 2024 [cited by applicant]
WO 2024261257A1 · 2024 [cited by applicant]
WO 2024264017A2 · 2024 [cited by applicant]
WO 2025016457A1 · 2025 [cited by applicant]
WO 2025043225A2 · 2025 [cited by applicant]
WO 2025049820A1 · 2025 [cited by applicant]
WO 2025049994A1 · 2025 [cited by applicant]
WO 2025062330A1 · 2025 [cited by applicant]
WO 2025076285A1 · 2025 [cited by applicant]
WO 2025207821A1 · 2025 [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2025/041205, dated Nov. 12, 2025, 13 pages. [cited by applicant]
Actis et al., Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs. J Med Chem. Feb. 13, 2025;68(3):3591-3611. [cited by applicant]
Eagon et al., Identification of Plasmodium falciparum falcilysin inhibitors by a virtual screen. Bioorg Med Chem Lett. Nov. 15, 2021;52:128394, 4 pages. [cited by applicant]
Liu et al., Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators. Eur J Med Chem. Feb. 5, 2023;247:115016, 12 pages. [cited by applicant]
Moloney et al., Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem. Mar. 2008;43(3):513-39. [cited by applicant]
Segura-Cabrera et al., Integrative computational protocol for the discovery of inhibitors of the Helicobacter pylori nickel response regulator (NikR). J Mol Model. Dec. 2011;17(12):3075-84. [cited by applicant]
Tieu et al., Heterocyclic acyl-phosphate bioisostere-based inhibitors of [cited by applicant]
Xu et al., Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core. Bioorg Med Chem. Aug. 15, 2016;24(16):3540-7. [cited by applicant]